Robert Andrew Berman
Known title: CEOCIK: 0001258360
Robert Andrew Berman's purchase track record
How the stock did after each of Robert Andrew Berman's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 16, 2021
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+18.6%
3 months: +14.6%
Beat the S&P 500
67%
median +20.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/19/2024 | NVNO | $31K | +14.6% | +60.1% | +1.7% |
| 6/27/2022 | NVNO | $10K | +52.5% | +18.6% | -1.8% |
| 11/16/2021 | NVNO | $31K | -33.3% | -45.9% | -13.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NVNO | ▲ Buy | Open Market | 12,000 | $31K | 12/19/2024 | View on chart |
| NVNO | ▲ Buy | Open Market | 2,500 | $10K | 6/27/2022 | View on chart |
| NVNO | ▲ Buy | Grant | 200,000 | — | 11/30/2021 | View on chart |
| NVNO | ▲ Buy | Open Market | 2,000 | $15K | 11/19/2021 | View on chart |
| NVNO | ▲ Buy | Open Market | 2,000 | $16K | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
enVVeno Medical to Showcase enVVe System at VEINS 2026 Summit
enVVeno Medical Corporation announced that its first-in-class enVVe system will be featured at The VEINS 2026 Innovation Summit. This event highlights the company's progress as it moves toward a U.S. pivotal trial for its medical technology. The announcement serves as a key milestone in the development timeline for the device.
enVVeno Medical to Showcase enVVe System at VEINS 2026 Summit. enVVeno Medical Corporation announced that its first-in-class enVVe system will be featured at The VEINS 2026 Innovation Summit. This event highlights the company's progress as it moves toward a U.S. pivotal trial for its medical technology. The announcement serves as a key milestone in the development timeline for the device.